Ind-Swift Limited (INDSWFTLTD.BO)

INR 28.0

(5.7%)

Market Cap (In INR)

1.51 Billion

Revenue (In INR)

5.02 Billion

Net Income (In INR)

142.31 Million

Avg. Volume

21.27 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
15.19-32.49
PE
-
EPS
-
Beta Value
-0.109
ISIN
INE788B01028
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Gopal Munjal M.D.
Employee Count
-
Website
https://www.indswiftltd.com
Ipo Date
2002-01-10
Details
Ind-Swift Limited develops pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynaecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial, anti-depressants, cardiology, diabetology, anti-allergic, neurology, and oncology. The company also provides Ayurvedic products, as well as contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries, as well as licenses its products to the United Kingdom, Europe, Canada, and Australia. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.